Bayhill Therapeutics Inc.

This article was originally published in Start Up

01 Sep 2003
Analysis

Mark Ratner mlratner@verizon.net

Executive Summary

By using DNA that encodes for self-antigens, Bayhill Therapeutics hopes to dampen or terminate the activities of TH1 helper cells involved in tissue destruction in autoimmune diseases, specifically multiple sclerosis, while at the same time activating TH2 cells to help combat the disease.

Already Registered? Sign in to continue reading.

New to Scrip? Start a free trial today!

Table
View full table

Topics

Industries
BioPharmaceutical

Related Companies

Related Deals

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

SC090791

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

SC090791

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Bayhill Therapeutics Inc.

Analysis

Executive Summary

Related Content

New Approaches to Treating Autoimmune Diseases

A Precarious Union: Combining Proprietary and Generic Businesses

A Precarious Union: Combining Proprietary and Generic Businesses

Topics

Related Companies

Related Deals

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert